Tirzepatide’s cardiovascular effects in clinical practice - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Tirzepatide’s cardiovascular effects in clinical practice

Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

  • By

  • Kathryn Wighton

  • August 28, 2026

  • 4 min

Share

Clinical Scorecard: Tirzepatide’s cardiovascular effects in clinical practice

At a Glance

CategoryDetail
ConditionType 2 diabetes with established atherosclerotic cardiovascular disease
Key MechanismsComparison of cardiovascular outcomes between tirzepatide and sitagliptin
Target PopulationPatients aged 40 years or older with type 2 diabetes and established atherosclerotic cardiovascular disease
Care SettingPopulation-based cohort study

Key Highlights

  • Tirzepatide associated with lower 1-year risk of major adverse cardiovascular events (MACE) compared to sitagliptin.
  • Weighted MACE risk: 3% with tirzepatide vs. 4% with sitagliptin.
  • Lower risks of myocardial infarction and all-cause mortality with tirzepatide.
  • Fewer infection-related hospital admissions with tirzepatide.
  • Study limited by short follow-up and potential residual confounding.

Guideline-Based Recommendations

Diagnosis

  • Patients should have documented previous myocardial infarction, ischemic stroke, or arterial disease.

Management

  • Consider tirzepatide for patients with type 2 diabetes and established cardiovascular disease.

Monitoring & Follow-up

  • Monitor for major adverse cardiovascular events during treatment.

Risks

  • Be aware of potential residual confounding affecting mortality findings.

Patient & Prescribing Data

Patients aged 40 years or older with type 2 diabetes and established atherosclerotic cardiovascular disease.

Tirzepatide may provide cardiovascular benefits compared to sitagliptin.

Clinical Best Practices

  • Utilize overlap weighting to balance baseline characteristics in treatment comparisons.
  • Assess absolute risk differences and number needed to treat for clinical decision-making.

Related Resources & Content

Original Source(s)

Tirzepatide’s cardiovascular effects in clinical practice

  • by Kathryn Wighton

  • August 28, 2026

Related Content

Macronutrients tested in weight loss

Investigators compared cardiometabolic responses to matched weight loss across ketogenic, Mediterranean, and plant-forward diets.

FDA updates PAH label with trial data

In adults diagnosed with pulmonary arterial hypertension within the previous year, adding sotatercept to background therapy reduced the risk of clinical worsening events by 76% compared with placebo.

TOFA may drive weight loss without reducing food intake

The oral compound increased energy expenditure, reduced fat mass, and improved metabolic measures in male mouse models.